The heart of insitro's strategy is the combination of advanced machine learning, biology at scale and molecular discovery that address bottlenecks in the drug development pipeline. To accomplish that, we are putting together an incredible team with a passion for target discovery and therapeutics advancement.
Reporting to the Oncology Discovery Therapeutic Area head, you will partner with data science and machine learning (DSML), translational oncology and computational biology colleagues to gain deep insights into the biology and efficacy of antibody drug conjugates (ADCs) with the goal of delivering therapeutics to the right patients. You will lead studies to validate ADC targets, evaluate linker and warhead strategies and support biomarker development. This will be a hybrid on-site/remote preclinical role, with opportunities to lead projects to drug candidate nomination. You are collaborative, creative, and rigorous and will excel in an exciting environment. This is an excellent opportunity for someone passionate about therapeutic discovery and making an impact on cancer patients!
You will join a growing techbio startup that has long-term stability but is very much in formation, providing many opportunities for impact. You will work with an accomplished versatile team with learning opportunities, and help shape insitro's culture, strategic direction, and outcomes. Join us, and help make a difference to patients!
Our target starting salary for successful US-based applicants for this role is $140,000 - $190,000. To determine starting pay, we consider multiple job-related factors including a candidate's skills, education and experience, market demand, business needs, and internal parity. We may also adjust this range in the future based on market data.
This role is eligible for participation in our Annual Performance Bonus Plan (based on company targets by role level and annual company performance) and our Equity Incentive Plan, subject to the terms of those plans and associated policies.
In addition, insitro also provides our employees:
insitro is an equal opportunity employer. All applicants will be considered for employment without attention to race, color, religion, sex, sexual orientation, gender identity, national origin, veteran or disability status.
We believe diversity, equity, and inclusion need to be at the foundation of our culture. We strive to bring together diverse teams–grounded in different expertise and life experiences–and ensure those teams succeed in inclusive, growth-oriented environments supported by equitable company and team practices. You can expect equitable treatment, respect, and fairness throughout the interview process.
About insitro
insitro is a drug discovery and development company using machine learning (ML) and data at scale to decode biology for transformative medicines. At the core of insitro’s approach is the convergence of in-house generated multi-modal cellular data and high-content phenotypic human cohort data. We rely on these data to develop ML-driven, predictive disease models that uncover underlying biologic state and elucidate critical drivers of disease. These powerful models rely on extensive biological and computational infrastructure and allow insitro to advance novel targets and patient biomarkers, design therapeutics and inform clinical strategy. insitro is advancing a wholly owned and partnered pipeline of insights and therapeutics in neuroscience, oncology and metabolism. Since launching in 2018, insitro has raised over $700 million from top tech, biotech and crossover investors, and from collaborations with pharmaceutical partners. For more information on insitro, please visit www.insitro.com.
Read Full Description